The biotechnology space is filled with new drug makers and treatments that help make lives better, and large pharma has typically tapped into these smaller innovators to fill out their own businesses. With increased merger and acquisition activity in the biotech sector, ETF investors may look to targeted plays to capture the up-and-coming companies.